[8-K] Grace Therapeutics, Inc. Reports Material Event
Grace Therapeutics, Inc. furnished a press release announcing its financial results for the three months ended June 30, 2025. The press release is attached to this report as Exhibit 99.1, and an Inline XBRL cover page is provided as Exhibit 104. The company states that the information in Item 2.02, including Exhibit 99.1, is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, which limits the filing liabilities for this disclosure.
The Form 8-K identifies the issuer as Grace Therapeutics (trading as GRCE on The Nasdaq Stock Market) and is signed by Chief Executive Officer Prashant Kohli. The Form itself does not include the detailed financial line items in-line; those figures are conveyed in the attached press release exhibit.
Grace Therapeutics, Inc. ha diffuso un comunicato stampa che annuncia i risultati finanziari per i tre mesi terminati il 30 giugno 2025. Il comunicato è allegato a questo rapporto come Allegato 99.1 e una pagina di copertina Inline XBRL è fornita come Allegato 104. La società dichiara che le informazioni al Punto 2.02, incluso l'Allegato 99.1, sono fornite e non sono considerate "filed" ai fini della Sezione 18 del Securities Exchange Act, limitando così le responsabilità di deposito per questa divulgazione.
Il Modulo 8-K identifica l'emittente come Grace Therapeutics (quotata con il simbolo GRCE sul Nasdaq) ed è firmato dall'Amministratore Delegato Prashant Kohli. Il Modulo stesso non include in linea le voci finanziarie dettagliate; tali cifre sono riportate nel comunicato stampa allegato.
Grace Therapeutics, Inc. publicó un comunicado de prensa con sus resultados financieros para los tres meses terminados el 30 de junio de 2025. El comunicado se adjunta a este informe como Anexo 99.1, y se incluye una portada Inline XBRL como Anexo 104. La empresa indica que la información en el Punto 2.02, incluido el Anexo 99.1, se proporciona y no se considera "presentada" a los efectos de la Sección 18 del Exchange Act, lo que limita la responsabilidad por esta presentación.
El Formulario 8-K identifica al emisor como Grace Therapeutics (que cotiza como GRCE en Nasdaq) y está firmado por el director ejecutivo Prashant Kohli. El propio Formulario no incluye en línea las partidas financieras detalladas; esas cifras aparecen en el comunicado de prensa adjunto.
Grace Therapeutics, Inc.는 2025년 6월 30일로 종료된 3개월간의 재무 실적을 발표하는 보도자료를 제출했습니다. 보도자료는 본 보고서에 Exhibit 99.1로 첨부되어 있으며, Inline XBRL 표지 페이지는 Exhibit 104로 제공됩니다. 회사는 Item 2.02의 정보(Exhibit 99.1 포함)가 제공된 것이며 Exchange Act 제18조 목적상 "filed"로 간주되지 않는다고 밝혀 이번 공시에 대한 제출 책임을 제한한다고 명시했습니다.
Form 8-K는 발행인을 Grace Therapeutics(나스닥 거래코드 GRCE)로 식별하며 최고경영자 Prashant Kohli가 서명했습니다. 해당 Form 자체에는 상세한 재무 항목이 인라인으로 포함되어 있지 않으며, 이러한 수치는 첨부된 보도자료에 제시되어 있습니다.
Grace Therapeutics, Inc. a diffusé un communiqué de presse annonçant ses résultats financiers pour les trois mois clos le 30 juin 2025. Le communiqué est joint à ce rapport en tant que Exhibit 99.1, et une page de couverture Inline XBRL est fournie en tant que Exhibit 104. La société indique que les informations figurant à l'Item 2.02, y compris l'Exhibit 99.1, sont fournies et ne sont pas considérées comme "filed" aux fins de la Section 18 de l'Exchange Act, ce qui limite les responsabilités liées au dépôt pour cette divulgation.
Le formulaire 8-K identifie l'émetteur comme Grace Therapeutics (cotée sous le symbole GRCE sur le Nasdaq) et est signé par le directeur général Prashant Kohli. Le formulaire lui-même n'inclut pas en ligne les postes financiers détaillés ; ces chiffres figurent dans le communiqué de presse ci-joint.
Grace Therapeutics, Inc. hat eine Pressemitteilung veröffentlicht, in der die Finanzergebnisse für die drei Monate zum 30. Juni 2025 bekanntgegeben werden. Die Pressemitteilung ist diesem Bericht als Exhibit 99.1 beigefügt, und eine Inline-XBRL-Titelseite ist als Exhibit 104 enthalten. Das Unternehmen erklärt, dass die Angaben in Punkt 2.02, einschließlich Exhibit 99.1, als "furnished" und nicht als "filed" im Sinne von Abschnitt 18 des Exchange Act zu betrachten sind, wodurch die Haftung aus der Einreichung für diese Offenlegung begrenzt wird.
Das Formular 8-K nennt den Emittenten Grace Therapeutics (Börsenkürzel GRCE an der Nasdaq) und ist vom Chief Executive Officer Prashant Kohli unterzeichnet. Das Formular selbst enthält die detaillierten Finanzposten nicht inline; diese Zahlen sind in der beigefügten Pressemitteilung ausgewiesen.
- None.
- None.
Insights
TL;DR: Routine 8-K furnishing of quarterly results; information is furnished, not filed, so the disclosure is standard and of limited standalone impact.
The Form 8-K reports that Grace Therapeutics furnished a press release with financial results for the three months ended June 30, 2025, attached as Exhibit 99.1, with an Inline XBRL cover page as Exhibit 104. Because the company explicitly states the exhibit is "furnished, not filed," the legal exposure under Section 18 is limited. The 8-K itself contains no financial line items in the body, so investors must review Exhibit 99.1 for the substantive numbers. This disclosure is a routine earnings-period filing and, absent material surprises in the press release, is unlikely to be market-moving by itself.
TL;DR: Governance-compliant disclosure; signature by the CEO and exhibit labeling are standard and pose no immediate governance concerns.
The filing follows typical governance and SEC disclosure practice by furnishing the earnings press release as an exhibit and including an Inline XBRL cover page. The CEO, Prashant Kohli, signed the report, which indicates executive-level attestation of the submission. The explicit language that the exhibit is "furnished, not filed" is standard and indicates the company is not incorporating the press release into prior filings. There are no governance red flags evident from the 8-K text provided.
Grace Therapeutics, Inc. ha diffuso un comunicato stampa che annuncia i risultati finanziari per i tre mesi terminati il 30 giugno 2025. Il comunicato è allegato a questo rapporto come Allegato 99.1 e una pagina di copertina Inline XBRL è fornita come Allegato 104. La società dichiara che le informazioni al Punto 2.02, incluso l'Allegato 99.1, sono fornite e non sono considerate "filed" ai fini della Sezione 18 del Securities Exchange Act, limitando così le responsabilità di deposito per questa divulgazione.
Il Modulo 8-K identifica l'emittente come Grace Therapeutics (quotata con il simbolo GRCE sul Nasdaq) ed è firmato dall'Amministratore Delegato Prashant Kohli. Il Modulo stesso non include in linea le voci finanziarie dettagliate; tali cifre sono riportate nel comunicato stampa allegato.
Grace Therapeutics, Inc. publicó un comunicado de prensa con sus resultados financieros para los tres meses terminados el 30 de junio de 2025. El comunicado se adjunta a este informe como Anexo 99.1, y se incluye una portada Inline XBRL como Anexo 104. La empresa indica que la información en el Punto 2.02, incluido el Anexo 99.1, se proporciona y no se considera "presentada" a los efectos de la Sección 18 del Exchange Act, lo que limita la responsabilidad por esta presentación.
El Formulario 8-K identifica al emisor como Grace Therapeutics (que cotiza como GRCE en Nasdaq) y está firmado por el director ejecutivo Prashant Kohli. El propio Formulario no incluye en línea las partidas financieras detalladas; esas cifras aparecen en el comunicado de prensa adjunto.
Grace Therapeutics, Inc.는 2025년 6월 30일로 종료된 3개월간의 재무 실적을 발표하는 보도자료를 제출했습니다. 보도자료는 본 보고서에 Exhibit 99.1로 첨부되어 있으며, Inline XBRL 표지 페이지는 Exhibit 104로 제공됩니다. 회사는 Item 2.02의 정보(Exhibit 99.1 포함)가 제공된 것이며 Exchange Act 제18조 목적상 "filed"로 간주되지 않는다고 밝혀 이번 공시에 대한 제출 책임을 제한한다고 명시했습니다.
Form 8-K는 발행인을 Grace Therapeutics(나스닥 거래코드 GRCE)로 식별하며 최고경영자 Prashant Kohli가 서명했습니다. 해당 Form 자체에는 상세한 재무 항목이 인라인으로 포함되어 있지 않으며, 이러한 수치는 첨부된 보도자료에 제시되어 있습니다.
Grace Therapeutics, Inc. a diffusé un communiqué de presse annonçant ses résultats financiers pour les trois mois clos le 30 juin 2025. Le communiqué est joint à ce rapport en tant que Exhibit 99.1, et une page de couverture Inline XBRL est fournie en tant que Exhibit 104. La société indique que les informations figurant à l'Item 2.02, y compris l'Exhibit 99.1, sont fournies et ne sont pas considérées comme "filed" aux fins de la Section 18 de l'Exchange Act, ce qui limite les responsabilités liées au dépôt pour cette divulgation.
Le formulaire 8-K identifie l'émetteur comme Grace Therapeutics (cotée sous le symbole GRCE sur le Nasdaq) et est signé par le directeur général Prashant Kohli. Le formulaire lui-même n'inclut pas en ligne les postes financiers détaillés ; ces chiffres figurent dans le communiqué de presse ci-joint.
Grace Therapeutics, Inc. hat eine Pressemitteilung veröffentlicht, in der die Finanzergebnisse für die drei Monate zum 30. Juni 2025 bekanntgegeben werden. Die Pressemitteilung ist diesem Bericht als Exhibit 99.1 beigefügt, und eine Inline-XBRL-Titelseite ist als Exhibit 104 enthalten. Das Unternehmen erklärt, dass die Angaben in Punkt 2.02, einschließlich Exhibit 99.1, als "furnished" und nicht als "filed" im Sinne von Abschnitt 18 des Exchange Act zu betrachten sind, wodurch die Haftung aus der Einreichung für diese Offenlegung begrenzt wird.
Das Formular 8-K nennt den Emittenten Grace Therapeutics (Börsenkürzel GRCE an der Nasdaq) und ist vom Chief Executive Officer Prashant Kohli unterzeichnet. Das Formular selbst enthält die detaillierten Finanzposten nicht inline; diese Zahlen sind in der beigefügten Pressemitteilung ausgewiesen.
FAQ
What did Grace Therapeutics (GRCE) disclose in this Form 8-K?
Does the Form 8-K state whether the press release is "filed" or "furnished"?
Which reporting period do the results cover in the disclosed press release?
Where is Grace Therapeutics (GRCE) traded?
Who signed the Form 8-K on behalf of Grace Therapeutics?
